Sulforaphane shows potential for hair regrowth, with users reporting reduced shedding and regrowth. Some users combine it with Minoxidil and finasteride for better results.
Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.
A 24 year old male struggling with the physical and mental effects of balding, being short, and having a micropenis. Suggested treatments include taking medications such as finasteride and minoxidil, lifting weights, and trying not to compare himself to others.
Accepting hair loss and not taking drastic measures like shaving your head if you are only mildly balding, and encouraging people to fight it with treatments such as finasteride, minoxidil, nizoral and microneedling. Additionally, it discusses the importance of being realistic when trying to restore hair and addressing the misconception that one must look a certain way in order to be attractive.
There have been no new effective hair loss treatments since finasteride, despite technological advancements. Current treatments include finasteride, minoxidil, and RU58841, with ongoing challenges and potential future solutions in research.
The conversation discusses the impact of finasteride on sexual function, with many users reporting reduced libido and weaker erections despite continuing the treatment to prevent hair loss. Some users suggest checking hormone levels or switching to different dosages or treatments like dutasteride, while others share mixed experiences regarding the severity of side effects.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
The conversation discusses a new model for understanding androgenetic alopecia (AGA), linking it to dietary and lifestyle factors similar to PCOS, and highlighting the role of DHT, vascular damage, and inflammation. Treatments mentioned include Minoxidil, finasteride, and RU58841.
This conversation discusses the results of a model who claims he went from almost a Norwood 3 to a perfect hairline in 8 months using only Minoxidil and Rosemary oil. The replies suggest that this could be realistic but long-term results would require additional treatments like finasteride or other medications to prevent further hair loss.
Iontophoresis and sonophoresis can enhance drug delivery into the scalp. Combining these methods may improve the effectiveness of topical treatments like dutasteride and certain peptides.
A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.
User shared successful hair regrowth results using Minoxidil and Microneedling with a Dr. Pen M8 model. Discussed routine, needle depth, and frequency for optimal results.
The post is about a user's successful hair regrowth over a year using daily finasteride and minoxidil. The user initially applied minoxidil twice daily, then reduced to a few times a week, and took oral finasteride every morning without side effects.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.
A user shared progress pictures of a hair transplant done in Toronto, Canada. The conversation includes comments on the appearance of Antonio Conte, with some suggesting he looked better after shaving his head.
The conversation is about individuals noticing others with full hair while experiencing their own hair loss. Some use treatments like Minoxidil and Finasteride, while others joke about noticing receding hairlines or suggest that hats and wigs are used to hide baldness.
Rating treatments for hair loss, with the help of GPT-4, according to efficacy, evidence and tolerability; a combination of chemicals from research papers, custom compounds, and some suggestions from other users were included.
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
Being overweight may increase finasteride side effects due to higher aromatase activity converting testosterone to estradiol. Maintaining a healthy weight could reduce these side effects.
The conversation discusses why the difference between donor and balding hair isn't studied more to find a cure for hair loss. Treatments mentioned include Minoxidil, finasteride, and RU58841.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
The conversation discusses the availability of GT20029, a new topical hair loss treatment with fewer side effects than Minoxidil or finasteride. Users suggest using finasteride to preserve hair until GT20029 becomes available.
The conversation is about someone's hair improvement after 5.5 years on finasteride, with various users commenting on the results and discussing their own experiences with hair loss treatments. Some users can't see a difference, while others inquire about the dosage used.
The conversation discusses the perception of increased hair loss among young men, with some attributing it to heightened awareness or environmental factors. Various treatments are mentioned, including Minoxidil, Finasteride, microneedling, scalp massages, and future hair transplant methods.
A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.
Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.
New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.
Finasteride may affect liver function and cortisol levels, potentially linking it to non-alcoholic fatty liver disease (NAFLD). More research is needed to understand this connection fully.